Health technology firm Royal Philips has partnered with artificial intelligence (AI) technology company PathAI to develop diagnostic solutions for diseases such as cancer.
The firms will work towards applying the AI to massive pathology data sets by building deep learning applications in computational pathology for better diagnostic and treatment decisions.
Initially, applications for automatic detection and quantification of cancerous lesions in breast cancer tissue will be developed.
PathAI chief executive officer Andy Beck said: "Our goal is to help patients receive fast, accurate diagnosis and support treating physicians to deliver optimal care by empowering pathologists with decision support tools powered by artificial intelligence.
"Research indicates that pathologists supported with computational tools could be both more accurate and faster."
Deep learning is an algorithmic technique that enables computers to analyse large amounts of data and automatically detect patterns, as well as make accurate predictions.
Philips Digital Pathology Solutions general manager Russ Granzow said: "Digitising images in pathology has the potential to transform the field by unlocking new opportunities in image recognition.
"With computational pathology and the application of artificial intelligence there is an opportunity to increase efficiencies, enable greater accuracy and precision, and allow pathologists to see things and access insights not previously available."
Philips has already deployed deep learning in its radiology clinical informatics solutions such as Illumeo and IntelliSpace Portal 9.0.
The firm has also created a digital pathology business following strategic investments, partnerships and technology licenses.
Image: Philips and PathAI aim to build deep learning applications in computational pathology to better inform diagnostic and treatment decisions. Photo: courtesy of PRNewsFoto/Royal Philips.